Your browser doesn't support javascript.
loading
Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction.
Prescott, Eva; Pernow, John; Saraste, Antti; Åkerblom, Axel; Angerås, Oskar; Erlinge, David; Grove, Erik L; Hedman, Marja; Jensen, Lisette O; Svedlund, Sara; Kjaer, Magnus; Lagerström-Fermér, Maria; Gan, Li-Ming.
Afiliação
  • Prescott E; Department of Cardiology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Pernow J; Division of Cardiology, Department of Medicine, Karolinska Institute, Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
  • Saraste A; University of Turku and Heart Centre, Turku University Hospital, Turku, Finland.
  • Åkerblom A; Department of Medical Sciences - Cardiology, and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
  • Angerås O; Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, and Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Erlinge D; Cardiology, Department of Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
  • Grove EL; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
  • Hedman M; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
  • Jensen LO; Department of Cardiothoracic Surgery, Heart Center, Kuopio University Hospital, Kuopio, Finland.
  • Svedlund S; Department of Cardiology, Odense University Hospital, Odense, Denmark.
  • Kjaer M; Department of Clinical Physiology, Sahlgrenska University Hospital, and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Lagerström-Fermér M; Early Biometrics and Statistical Innovation, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Gan LM; Research and Early Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Contemp Clin Trials Commun ; 19: 100629, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32875138
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Revista: Contemp Clin Trials Commun Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Dinamarca
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Revista: Contemp Clin Trials Commun Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Dinamarca